Inhibrx Biosciences, Inc.
INBX
$29.53
$0.431.48%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 1,200.00% | -- | -93.88% | -- | 233.33% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1,200.00% | -- | -93.88% | -- | 233.33% |
| Cost of Revenue | -94.59% | -70.04% | -59.35% | 2.20% | -14.33% |
| Gross Profit | 99.03% | 70.04% | 58.65% | -2.52% | 14.54% |
| SG&A Expenses | -93.12% | -39.60% | -759.31% | 0.19% | 1,185.50% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -82.18% | -41.89% | -120.06% | 1.85% | 289.18% |
| Operating Income | 82.98% | 41.89% | 120.55% | -2.12% | -289.22% |
| Income Before Tax | -101.54% | 44.97% | 48.87% | 15.30% | 4,049.27% |
| Income Tax Expenses | 0.00% | -- | 100.00% | -- | -60.00% |
| Earnings from Continuing Operations | -101.54% | 44.97% | 48.86% | 15.30% | 4,048.85% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -101.54% | 44.97% | 48.86% | 15.30% | 4,048.85% |
| EBIT | 82.98% | 41.89% | 120.55% | -2.12% | -289.22% |
| EBITDA | 83.34% | 42.52% | 121.40% | -1.13% | -290.84% |
| EPS Basic | -101.46% | 51.48% | 55.27% | 35.45% | 3,047.28% |
| Normalized Basic EPS | 83.44% | 51.48% | 118.88% | 35.45% | -159.36% |
| EPS Diluted | -101.48% | 51.48% | 55.25% | 35.36% | 3,009.82% |
| Normalized Diluted EPS | 83.22% | 51.48% | 118.88% | 35.45% | -156.07% |
| Average Basic Shares Outstanding | 5.81% | 13.41% | 14.33% | 31.22% | 33.98% |
| Average Diluted Shares Outstanding | 4.46% | 13.41% | 14.33% | 31.22% | 35.71% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |